ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / NAUT / insiders
LAB (27) CTKB (45) PACB (44) QTRX (22) ⌘ Pro Terminal β†’

Nautilus Biotechnology Inc. (NAUT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.73 -13.06% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.66

Nautilus Biotechnology Inc. (NAUT) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (43/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ SELL / AVOID Cap $347.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NAUT Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NAUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Nautilus Biotechnology Inc. (NASDAQ: NAUT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.73 (-13.06% 1D, market cap $347.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NAUT ranks #408 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NAUT compare to LAB and CTKB in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), NAUT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, LAB (Standard BioTools Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $240.7M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M). Among the 5-stock peer group, NAUT leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NAUT?
β–Ό

Per NAUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001808805), Nautilus Biotechnology Inc. generated $0 in revenue, -$59.0M in net income, and -$52.0M in free cash flow against $191.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.66 (-2.54%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (43/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D-
025507510043
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D
Cash (7)Whales (14)SEC (10)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.6% Base Target
$5 Bull$3 Base$2 Bear
πŸ“¬ FREE NAUT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NAUT)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
πŸ” WHY NAUT SCORES 43/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
35
Grade E$2.05+24.4% Next Q
Q2 (-2Q)
38
Grade E$2.55+13.3% Next Q
Q3 (-1Q)
40
Grade D$2.89-5.5% Next Q
Current
43
Grade D-$2.73-6.7% Hist 90D Ξ±
Trajectory: E (35) β†’ D- (43)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NAUT Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NAUT currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.67) and Max Pain ($2.87) forces dealer call-delta covering toward $4.53.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAUTβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNAUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

NAUT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NAUT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NAUT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAUT)

  • βœ“Walkthrough of NAUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NAUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.54%β–² ASCENDING CHANNEL
2026-11-03O $3.14H $3.14L $2.73C $2.73VOL 8.07M
RES: $3.47SUP: $0.93SMA50: $1.67SMA200: $2.13
$3.60$2.85$2.10$1.36$0.61RES $3.47SUP $0.93$2.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NAUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NAUT Butterfly Map β†’ + Track NAUT β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NAUT today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NAUT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAUT)

Health Care Rank #408 of 1016 βš”οΈ LAB vs NAUT Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NAUT vs. LAB, CTKB, PACB, QTRX)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nautilus Biotechnology Inc. (NAUT) ranks #408 by composite RQD confidence (43/100, grade D-) and #499 by equity capitalization ($347.7M). Within this direct 5-issuer industry benchmark cohort, NAUT leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. CTKB currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with NAUT at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NAUT ACTIVE
Nautilus Biotechnology Inc.
D- 43/100 β€” β€” -35.0% -13.06% $347.7M Benchmark Subject
LAB
Standard BioTools Inc.
E 27/100 β€” 49.9% -28.7% -1.61% $240.7M /lab-vs-naut β†’
CTKB
Cytek Biosciences Inc.
D 45/100 β€” 51.8% -12.7% -2.70% $796.8M /ctkb-vs-naut β†’
PACB
Pacific Biosciences of California Inc.
D 44/100 β€” 28.6% -35.0% -10.17% $809.7M /pacb-vs-naut β†’
QTRX
Quanterix Corporation
E 22/100 β€” 46.8% -35.0% -7.63% $137.4M /qtrx-vs-naut β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001808805

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nautilus Biotechnology Inc. (NAUT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$59.0M, operating cash flow of -$50.7M, and free cash flow of -$52.0M (+15.2% YoY). On the balance sheet, NAUT closed FY2025 with $191.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$59.0M -$50.7M -$52.0M $191.1M β€”
FY2024 (FY) 2024-12-31 $0 -$70.8M -$59.1M -$61.3M $242.7M β€”
FY2023 (FY) 2023-12-31 $0 -$63.7M -$51.7M -$51.7M β€” β€”

3. NAUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NAUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nautilus Biotechnology Inc. (NASDAQ: NAUT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.73 (-13.06% 1D, market cap $347.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NAUT ranks #408 in composite RQD confidence.

How does NAUT compare to LAB and CTKB in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), NAUT carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, LAB (Standard BioTools Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -28.7%, cap $240.7M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M). Among the 5-stock peer group, NAUT leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NAUT?

Per NAUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001808805), Nautilus Biotechnology Inc. generated $0 in revenue, -$59.0M in net income, and -$52.0M in free cash flow against $191.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NAUT trading relative to its 50-day, 200-day, and 52-week technical levels?

NAUT last traded at $2.73 (-13.06% on volume of 8,069,149 shares), positioning the stock +63.47% above its 50-day simple moving average ($1.67) and +28.17% above its 200-day simple moving average ($2.13). Across its 52-week range of $0.84 to $4.31, NAUT sits at the 54.5% percentile with a 14-day RSI of 55.5 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($2.39 to $3.07).

NAUT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are NAUT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NAUT leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: NAUT RQD Cockpit NAUT 12M Forecast NAUT Earnings & Move NAUT Dividends & DRIP NAUT Insiders & 13F NAUT Whale Options NAUT Profit Sankey NAUT News & Why
ROARABLE RATING BRIEF β€’ RQD 43/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

NAUT β€” Nautilus Biotechnology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:00Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NAUT scores 43 out of 100 with a letter grade of D-, labeled "Roarable Sell β€” Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -12.99%. For a prospective investor, this pillar signals that the business is currently consuming capital rather than generating it, which weighs heavily on the score.
  • Whale 13F Flow: 14 / 20. Per the Roarable RQD rating, this reflects institutional accumulation and options positioning. This is one of the stronger pillars, indicating some institutional interest even though fundamentals are weak.
  • Insider Conviction: 3 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider-driven conviction signals in the data.
  • Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. This pillar suggests the stock tracks the broader market without a distinct macro tailwind.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this reflects an Altman Z of 2.5, a Piotroski F of 3/9, and Debt/Equity of 0.5. This is a mid-range reading that points to balance-sheet strain rather than acute distress.

Practically, the investor implication is that upside depends on a turn in cash generation, which the current data does not show. The valuation tradeoff is that the market cap of $399.9M sits against negative cash flow, so any path to upside rests on future execution rather than current earnings power. Whale and news-driven interest may support near-term trading activity, but the weak cash engine and forensic pillars argue for caution.

Business

Nautilus Biotechnology Inc. (NAUT) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Laboratory Analytical Instruments industry. Per the company profile, the market capitalization is $0.4B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each period provided.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$0.0M$-59.0MN/A$-52.0M$12.4MN/A
FY 2024$0.0M$0.0M$-70.8MN/A$-61.3M$27.6MN/A
FY 2023$0.0M$0.0M$-63.7MN/A$-51.7MN/AN/A

Per the SEC financials, reported revenue and operating income are $0.0M in each period, and net losses are present in all three years. Gross, operating, and net margins are each 0% per the market data section. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9. Cash declined from $27.6M in FY 2024 to $12.4M in FY 2025 per the SEC financials, and debt is listed as N/A in the source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six items reference NAUT. Headlines include a Roth price target of $3.50 reported as bullish, a Seeking Alpha piece described as bullish on an upcoming "Voyager" launch, and a Stock Titan item about a 5:30 a.m. Pacific webcast covering results and outlook. Items are tagged with signal lights (GREEN or YELLOW) and impact labels (CATALYST or MARKET WIRE). Risk watch items are not separately identified in the source data. Per the Butterfly supply-chain graph, no proprietary signals are present.

Open Questions

  • What are NAUT's products, customers, and revenue model, given that reported revenue is $0.0M in every period?
  • What is the company's cash runway given cash of $12.4M against FY 2025 free cash flow of $-52.0M?
  • What is the debt position, since debt is listed as N/A across all periods?
  • What does the "Voyager" launch referenced in the news involve, and what is its timing?
  • What are the forward earnings and valuation metrics, given that P/E, forward P/E, and EV/EBITDA are unavailable?

NAUT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nautilus Biotechnology Inc. (NAUT) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NAUT Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NAUT Bull vs. Bear Conversation Board β€” What's Your Call at $2.73?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NAUT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on NAUT:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.76 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is NAUT (D- β€’ RQD 43/100) a Buy at $3.14?

Welcome to the NAUT (Nautilus Biotechnology Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.39 (-23.9%)
Spot @ $3.14

Pump the brakes on NAUT β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NAUT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Nautilus Biotechnology Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $3.67 (+16.9%)
Spot @ $3.14

NAUT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NAUT, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $3.14 (52-wk range $0.84 - $4.31), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%